<DOC>
	<DOCNO>NCT01780259</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics ( body medication ) intranasally ( nose ) administer esketamine healthy participant .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics , Safety , Tolerability Intranasally Administered Esketamine Healthy Participants</brief_title>
	<detailed_description>This single-center study 3 cohort ( group ) . Approximately 58 participant enrol study . In Cohort 1 , approximately 16 participant enrol 78 day receive 4 different single-dose regimen ( Treatment A , B , C D ) intranasal spray esketamine solution crossover manner ( participant switch one single-dose regimen another ) open label manner ( investigator participant know intervention receive participant ) . In Cohort 2 , approximately 14 participant enrol 35 day receive 1 regimen intranasal esketamine ( Treatment D ) open label manner . In Cohort 3 , approximately 28 participant enrol randomly assign receive either Treatment E ( intranasal esketamine spray ) Treatment F ( intranasal placebo spray ) double blind manner ( investigator participant know intervention receive participant ) . Safety evaluation include assessment adverse event , target nasal examination , laboratory test , electrocardiogram , physical examination , pulse oximetery , vital sign .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Triazolam</mesh_term>
	<criteria>Blood pressure 90 145 mmHg systolic high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function Agree protocoldefined method contraception Comfortable selfadministration intranasal medication History current clinically significant medical illness include cardiac arrhythmia cardiac disease ; hematologic disease ; coagulation disorder ; significant pulmonary disease , include bronchospastic respiratory disease ; diabetes mellitus ; renal hepatic insufficiency ; thyroid disease ; neurologic psychiatric disease , asthma Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram screen admission study center Known allergy heparin history heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Intranasal</keyword>
</DOC>